- Home
- ROIV vs DOCS Comparison
ROIV vs DOCS Comparison
Compare ROIV & DOCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- DOCS
- Stock Information
- Founded
- ROIV 2014
- DOCS 2010
- Country
- ROIV United Kingdom
- DOCS United States
- Employees
- ROIV N/A
- DOCS 827
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- DOCS Retail: Computer Software & Peripheral Equipment
- Sector
- ROIV Health Care
- DOCS Technology
- Exchange
- ROIV Nasdaq
- DOCS Nasdaq
- Market Cap
- ROIV 8.4B
- DOCS 10.4B
- IPO Year
- ROIV N/A
- DOCS 2021
- Fundamental
- Price
- ROIV $11.27
- DOCS $55.53
- Analyst Decision
- ROIV Strong Buy
- DOCS Hold
- Analyst Count
- ROIV 8
- DOCS 16
- Target Price
- ROIV $17.93
- DOCS $52.69
- AVG Volume (30 Days)
- ROIV 5.1M
- DOCS 1.9M
- Earning Date
- ROIV 02-11-2025
- DOCS 02-06-2025
- Dividend Yield
- ROIV N/A
- DOCS N/A
- EPS Growth
- ROIV N/A
- DOCS 50.58
- EPS
- ROIV 5.89
- DOCS 0.87
- Revenue
- ROIV $129,128,999.00
- DOCS $516,849,000.00
- Revenue This Year
- ROIV $15.98
- DOCS $15.79
- Revenue Next Year
- ROIV N/A
- DOCS $10.34
- P/E Ratio
- ROIV $1.91
- DOCS $63.47
- Revenue Growth
- ROIV 145.68
- DOCS 15.29
- 52 Week Low
- ROIV $9.69
- DOCS $22.96
- 52 Week High
- ROIV $13.06
- DOCS $61.75
- Technical
- Relative Strength Index (RSI)
- ROIV 46.46
- DOCS 56.25
- Support Level
- ROIV $10.89
- DOCS $49.01
- Resistance Level
- ROIV $11.26
- DOCS $57.15
- Average True Range (ATR)
- ROIV 0.36
- DOCS 1.87
- MACD
- ROIV -0.02
- DOCS -0.18
- Stochastic Oscillator
- ROIV 47.75
- DOCS 80.15
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About DOCS Doximity Inc.
Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.